|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<i>In silico</i> analyses of The Cancer Genome Atlas data sets revealed consistent correlations between the expression of the transcripts encoding LRIG1 and its interactors ZBTB16 and PTPRK and inverse correlations between the transcripts encoding LRIG1 and GLRX3.
|
29317492 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<i>In silico</i> analyses of The Cancer Genome Atlas data sets revealed consistent correlations between the expression of the transcripts encoding LRIG1 and its interactors ZBTB16 and PTPRK and inverse correlations between the transcripts encoding LRIG1 and GLRX3.
|
29317492 |
2018 |
|
QRS complex feature
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
52 Genetic Loci Influencing Myocardial Mass.
|
27659466 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT--PCR and immunohistochemical analysis.
|
14520461 |
2003 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
LRIG1-3 mRNA was detected in all human glioma cell lines and matched glioma samples, with large differences in the expression levels.
|
16532360 |
2006 |
|
Malignant neoplasm of urinary bladder
|
0.040 |
Biomarker
|
disease |
BEFREE |
LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87.
|
16978290 |
2006 |
|
Bladder Neoplasm
|
0.040 |
Biomarker
|
disease |
BEFREE |
LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87.
|
16978290 |
2006 |
|
Carcinoma of bladder
|
0.040 |
Biomarker
|
disease |
BEFREE |
LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87.
|
16978290 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 might act as a tumour-suppressor gene, participating in negative feedback control of EGFR expression, which inhibits bladder cancer cells from growth, migration and invasion.
|
16978290 |
2006 |
|
Tumor Cell Invasion
|
0.080 |
AlteredExpression
|
phenotype |
BEFREE |
LRIG1 might act as a tumour-suppressor gene, participating in negative feedback control of EGFR expression, which inhibits bladder cancer cells from growth, migration and invasion.
|
16978290 |
2006 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Lrig1 is expressed at low levels in several cancer types but is overexpressed in some prostate and colorectal tumors.
|
21821674 |
2011 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Lrig1 is expressed at low levels in several cancer types but is overexpressed in some prostate and colorectal tumors.
|
21821674 |
2011 |
|
Colorectal Neoplasms
|
0.110 |
AlteredExpression
|
group |
BEFREE |
Lrig1 is expressed at low levels in several cancer types but is overexpressed in some prostate and colorectal tumors.
|
21821674 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.
|
22241084 |
2012 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.
|
22241084 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 functions as a tumor suppressor in the pathogenesis of glioma via EGFR/Akt/c-Myc activation.
|
23124613 |
2013 |
|
Glioma
|
0.200 |
Biomarker
|
disease |
BEFREE |
LRIG1 functions as a tumor suppressor in the pathogenesis of glioma via EGFR/Akt/c-Myc activation.
|
23124613 |
2013 |
|
Squamous cell carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development.
|
23208928 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) are an inhibitor of receptor tyrosine kinases (RTKs) that was discovered in recent years, and many studies showed that LRIG1 is a tumor suppressor gene and may be related to tumor drug resistance.
|
25048475 |
2014 |
|
Glioma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
LRIG1 was negatively correlated with BCL-2 expression in glioma tissue and U251/MDR cells, and upregulation of LRIG1 can enhance chemosensitivity and inhibit BCL-2 expression.
|
25048475 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 is a negative regulator of growth factor signaling that has been shown to function as a tumor suppressor in vitro and in vivo in mice.
|
25180912 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LRIG1 negatively regulates multiple receptor tyrosine kinases signaling including the epidermal growth factor receptor (EGFR) and is a proposed tumor suppressor.
|
25353163 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) is a newly discovered tumor suppressor which involved in regulation of chemosensitivity in various human cancer cells.
|
26097540 |
2015 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
LRIG1, a 3p tumor suppressor, represses EGFR signaling and is a novel epigenetic silenced gene in colorectal cancer.
|
26159916 |
2015 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
LRIG1 expression has prognostic significance in various human cancers.In this study, we first used the quantitative polymerase chain reaction (qPCR) and immunohistochemical analysis of 36 and 182 NSCLC patient tissues to analyze the LRIG1 expression respectively.
|
26632716 |
2015 |